Objective To investigate the efficacy and side-effect of tetrandrine (Tet) combined with 125I seed implan-tation in treatment of locally advanced none-small-cell lung cancer ( NSCLC) .Methods Seventy-six patients with clinical stage Ⅲa-Ⅲb NSCLC were randomly divided into two groups: the observation group and the control group , 38 in each group.All patients were treated with 125 I seed implantation guided by CT .The prescribed dose was 110 Gy.Patients in the observation group were treated with Tet 40mg 3 times per day for 3 months since 125 I seed implantation.The efficacy and toxicity of the two groups were compared .Results All 76 patients completed the seed implantation successfully .D100 was (112.4 ±12.3)Gy, D90 was (148.7 ±22.5)Gy and mean dose was (238.9 ±11.6)Gy.With the follow-up of 21 month, the total response rates of the observation group and the control group were 86 .8%and 65 .8%, 1-year survival rates were 84.2%and 63.2%, and the median survival time were 26 and 18 months respectively (all P<0.05).The major compli-cations were pneumothorax and blood sputum .Eight patients in the control group suffered 1 degree late radioactive pulmo-nary damage and none in the observation group .Conclusion Tet combined with 125 I seed implantation for locally advanced NSCLC shows good short-term effect, high local control rate, high survival rate, less complications and no obvious adverse reactions , which is worthy of clinical application .%目的：探讨放射性125 I粒子联合汉防己甲素（ Tet）治疗局部晚期非小细胞肺癌（ NSCLC）的疗效及安全性。方法将76例Ⅲa～Ⅲb期NSCLC患者随机分为两组各38例。两组均在CT引导下将125 I粒子植入靶区，放射处方剂量为110 Gy。观察组在植入125 I粒子当天口服Tet，连服3个月。比较两组的疗效和毒性反应。结果76例患者均顺利完成治疗。 D100（112．4±12．3）Gy，D90（148．7±22．5）Gy，平均剂量（238．9±11．6）Gy。中位随访时间为21个月，观察组和对照组治疗6个月时的总有效率分别为86．8％、65．8％，1年生存率分别为84．2％、63．2％，中位生存时间分别为26、18个月（P均＜0．05）。125I粒子植入的主要并发症为气胸及咯血，对照组出现1级晚期放射性肺损伤8例，观察组未出现晚期放射性肺损伤。结论125 I粒子联合Tet治疗局部晚期NSCLC近期疗效好、局部控制率高、患者生存率高、并发症少、无明显不良反应，值得临床应用。
展开▼
